In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
Weight-loss Drugs
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
Rapid weight reduction might raise the risk of osteoporosis and reduce muscular mass. However, there is now excellent news for those who may be at danger when taking weight loss medications. According to a recent study from Aarhus University, the adverse effects can be mitigated by the medication bimagrumab.
In 2022–2023, the researchers found people diagnosed with obesity without diabetes using a nationwide sample of medical insurance claims data from over 17 million persons with private insurance.
